In other studies of pathogenic infection and mucosal surface damage, this new drug has been shown to reduce inflammation at the surface. Since cystic fibrosis is a disease severely affected by airway inflammation, future studies will also examine the drug’s potential additional role in mitigating pulmonary inflammation.
“The preliminary data are extremely exciting,” stated Dr. Steven Rowe, “and could provide a new avenue to address mucus stasis in CF lung disease, potentially improving lung health.”
Preliminary results from these studies will be presented in October at the 27th Annual North American Cystic Fibrosis Conference. Synedgen hopes its new drug will make the sputum flow more freely, break up pathogenic biofilms and also enhance activity of standard antibiotics, providing a new and highly effective pulmonary treatment to help CF patients breathe more easily and combat lung infections.
Research reported in this press release was supported by the National Heart Lung and Blood Institute of the National Institutes of Health under award number 1R43HL118867. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product develop
Copyright©2012 Vocus, Inc.
All rights reserved